Bufexamac

CAS : 2438-72-4

Ref. 3D-CAA43872

Informations sur le produit

• Nom: Bufexamac
• Synonymes: 2-(4-Butoxyphenyl)Acetohydroxamic Acid, 2-(4-butoxyphenyl)-N-hydroxyacetamide, 2-(p-Butoxyphenyl)acetohydroxamic acid, 4-Butoxy-N-hydroxybenzeneacetamide, 4-Butoxyphenylacethydroxamic acid, Acetohydroxamic acid, 2-(p-butoxyphenyl)-, Anderm, Benzeneacetamide, 4-butoxy-N-hydroxy-, Bufexamic acid, Cp 1044J3, Droxarol, Droxaryl, Feximac, Flogocid, Flogocid N plastigel, Malipuran, Mofenar, Norfemac, Parfenac, Parfenal, Trolab, p-Butoxyphenylacethydroxamic acid, p-Butoxyphenylacetohydroxamic acid

Description

Bufexamac is a non-steroidal antiinflammatory drug that belongs to the class of pyridyl-2-one derivatives. It inhibits matrix metalloproteinase (MMP) activity and has been shown to inhibit the activity of MMP-9 in a statistically significant manner. Bufexamac also binds to DNA, inhibiting bacterial growth by binding to dna binding activity. In addition, bufexamac nanoparticulate compositions have been shown to have uv absorption and can be used for diagnosis. The antioxidative properties of bufexamac may reduce cancer risk and inflammatory skin diseases such as psoriasis. Bufexamac has been shown to be an effective treatment for chronic schizophrenia and other mental illnesses with high body mass index. Further, bufexamac has been found to bind specifically to the enzyme responsible for fragmentation of amyloid precursor protein (APP).

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 223.27 g/mol
• Formule: C₁₂H₁₇NO₃
• Degré de pureté: Min. 95%